1. Home
  2. CSTL vs SHEN Comparison

CSTL vs SHEN Comparison

Compare CSTL & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • SHEN
  • Stock Information
  • Founded
  • CSTL 2007
  • SHEN 1902
  • Country
  • CSTL United States
  • SHEN United States
  • Employees
  • CSTL N/A
  • SHEN N/A
  • Industry
  • CSTL Medical Specialities
  • SHEN Telecommunications Equipment
  • Sector
  • CSTL Health Care
  • SHEN Telecommunications
  • Exchange
  • CSTL Nasdaq
  • SHEN Nasdaq
  • Market Cap
  • CSTL 661.7M
  • SHEN 719.2M
  • IPO Year
  • CSTL 2019
  • SHEN N/A
  • Fundamental
  • Price
  • CSTL $33.85
  • SHEN $11.24
  • Analyst Decision
  • CSTL Strong Buy
  • SHEN Strong Buy
  • Analyst Count
  • CSTL 6
  • SHEN 1
  • Target Price
  • CSTL $38.67
  • SHEN $26.00
  • AVG Volume (30 Days)
  • CSTL 391.5K
  • SHEN 292.7K
  • Earning Date
  • CSTL 11-03-2025
  • SHEN 10-29-2025
  • Dividend Yield
  • CSTL N/A
  • SHEN 0.87%
  • EPS Growth
  • CSTL N/A
  • SHEN N/A
  • EPS
  • CSTL N/A
  • SHEN N/A
  • Revenue
  • CSTL $343,530,000.00
  • SHEN $351,674,000.00
  • Revenue This Year
  • CSTL N/A
  • SHEN $10.78
  • Revenue Next Year
  • CSTL N/A
  • SHEN $5.51
  • P/E Ratio
  • CSTL N/A
  • SHEN N/A
  • Revenue Growth
  • CSTL 10.15
  • SHEN 13.24
  • 52 Week Low
  • CSTL $14.59
  • SHEN $9.77
  • 52 Week High
  • CSTL $35.84
  • SHEN $16.28
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 85.44
  • SHEN 25.68
  • Support Level
  • CSTL $23.31
  • SHEN $12.03
  • Resistance Level
  • CSTL $34.36
  • SHEN $13.44
  • Average True Range (ATR)
  • CSTL 1.46
  • SHEN 0.49
  • MACD
  • CSTL 1.10
  • SHEN -0.17
  • Stochastic Oscillator
  • CSTL 95.87
  • SHEN 6.47

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

Share on Social Networks: